Estradiol

Estradiol (17β-estradiol) is the primary and most potent endogenous estrogen produced by the ovaries during reproductive years. It is a steroid hormone that acts through binding to nuclear estrogen receptors (ERα and ERβ), which are distributed throughout the body in tissues including the uterus, breast, bone, cardiovascular system, brain, and liver, among others. Estradiol is responsible for the development and maintenance of female secondary sexual characteristics, regulation of the menstrual cycle, bone density preservation, cardiovascular function, and a range of central nervous system effects including effects on mood, sleep, and cognition.¹

At menopause, ovarian estradiol production declines substantially, producing the physiological changes and symptoms associated with menopause (vasomotor symptoms, vaginal atrophy, accelerated bone loss). Pharmaceutical estradiol for menopausal hormone therapy (MHT, sometimes called hormone replacement therapy or HRT) is available in multiple formulations including oral tablets, transdermal patches, transdermal gels and sprays, vaginal rings, vaginal creams, and injectable forms. Estradiol is also used in gender-affirming hormone therapy for transgender women and non-binary individuals.

FDA-approved indications vary somewhat by formulation and dosage form; the following covers the major indications for estradiol products:¹

• Treatment of moderate to severe vasomotor symptoms due to menopause (hot flashes, night sweats).
• Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause (dryness, itching, painful intercourse).
• Prevention of postmenopausal osteoporosis (when prescribing solely for this indication, non-estrogen medications should be considered first).
• Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian insufficiency.

Off-label uses include: Gender-affirming feminizing hormone therapy; treatment of premenstrual dysphoric disorder; use during fertility treatment protocols.

Dosing varies significantly by delivery route and formulation:¹

• Oral tablets: Typically 0.5 mg to 2 mg daily. Used in combination with a progestogen in women with an intact uterus (to prevent endometrial hyperplasia).
• Transdermal patches: Replaced once or twice weekly depending on the product; doses range from approximately 0.025 mg to 0.1 mg per day delivered transdermally.
• Transdermal gels/sprays: Applied daily; estradiol gel is commonly dosed at 0.25 g to 1 g (providing 0.25 mg to 0.75 mg estradiol per day depending on the product).
• Vaginal formulations: Lower-dose products intended for local effects on vaginal tissue; generally have minimal systemic absorption.

The general principle from the FDA label and clinical guidelines is to use the lowest effective dose for the shortest duration consistent with individual treatment goals and risk profile, with periodic reassessment.¹

Oral, transdermal (patch, gel, spray), vaginal (ring, cream, suppository), or intramuscular injection (less common in the U.S. for menopause indications; used in some TRT and gender-affirming protocols).

Storage varies by formulation. Oral tablets: room temperature, away from heat and moisture. Transdermal patches and gels: room temperature, away from heat and direct sunlight. Refrigeration is not required for most formulations; check individual product labeling for specifics.

Boxed warning: Estrogens increase the risk of endometrial cancer in women with an intact uterus who are taking estrogen alone (without a progestogen). They should not be used to prevent cardiovascular disease or dementia.¹

The Women's Health Initiative (WHI) — a large, long-term, randomized clinical trial that enrolled approximately 27,000 predominantly healthy postmenopausal women — generated landmark safety data on menopausal hormone therapy. The combined estrogen-plus-progestin arm of the trial was stopped early because of an observed increase in invasive breast cancer and because overall health risks (including increased risks of coronary heart disease, stroke, and pulmonary embolism) exceeded benefits in the study population. The estrogen-alone arm (in women without a uterus) did not show increased breast cancer risk and showed reduced hip fracture risk, but showed increased stroke risk. The WHI findings substantially changed clinical practice and are the basis for the boxed warnings present on all systemic estrogen products.¹

Important nuances on WHI applicability: The WHI used conjugated equine estrogens (not estradiol) in oral formulations in older postmenopausal women (mean age 63). Subsequent research suggests that the timing of initiation matters — initiating estrogen therapy closer to the onset of menopause (the "timing hypothesis" or "window of opportunity") may confer a more favorable risk-benefit profile than initiating a decade or more after menopause. Transdermal estradiol avoids hepatic first-pass metabolism and has a different risk profile than oral estrogens, particularly regarding VTE risk. These distinctions are actively discussed in the clinical literature and society guidelines but are not yet fully resolved.

Additional considerations:¹

• Uterine protection: Women with an intact uterus taking systemic estrogen require concurrent progestogen therapy to prevent endometrial hyperplasia and cancer.
• Breast cancer: Estrogen-alone therapy does not clearly increase breast cancer risk; combined estrogen-progestogen therapy has been associated with a modest increase. This risk must be weighed individually.
• Venous thromboembolism (VTE): Oral estrogens increase VTE risk; transdermal estrogens appear to carry substantially lower VTE risk based on observational data.
• Drug interactions: Estrogens affect thyroid-binding globulin and may increase requirements for thyroid hormone replacement in hypothyroid patients.